HOME最近の話題次回の研究会研究会の歩み役立ち情報keywords意見交換リンク

2008年9月24日(水)

??????????????????

投稿者: ????????

??????????????????????cardiovascular risks???????????????????????????????

?JAMA ???????????????????????????????????????????????????????????????17??14783???????????????????????????????????????????????????????1.58??????????1.80???????????1.53?????????????stroke?1.46???????????????????????????????????????

?????6????????????????????????????????????1.73???????????

Inhaled Anticholinergics and Risk of Major Adverse Cardiovascular Events in Patients With Chronic Obstructive Pulmonary Disease
???JAMA. 2008;300(12):1439-1450?
???http://jama.ama-assn.org/cgi/content/abstract/300/12/1439

???Ann Intern Med ??????????????????COPD?????????????????????????????

Risk for Death Associated with Medications for Recently Diagnosed Chronic Obstructive Pulmonary Disease
???Ann Intern Med 2008; 149: 380-390?
??http://www.annals.org/cgi/content/full/149/6/380

?????????????????Nested case-control study???????????????????????????????????????????????????????????????????

????????????????????????????????????????????????????1.34??????????

??????????????????????????????????????????????????COPD?????????????????????????????????????????????????????????????????????

???????????????????????????Boehringer Ingelheim??23??37??5993?????????UPLIFT (Understanding Potential Long-term Impacts on Function with Tiotropium)???30??????????????19545????????????????????? ????????????????????????????????????????????????????????????????

Established Safety Profile of Spiriva Confirmed by 30 Rigorously Controlled Clinical Trials and the Landmark Trial UPLIFT
???Boehringer Ingelheim????????2008.9.23?
???http://us.boehringer-ingelheim.com/newsroom/2008/09-23-08_spiriva_safety.html

?????????????????????????????????????????????Early Coumunication???3?18?????????????FDA????????10?7??Update?????????????FDA??????????????????

????????Vol.6?No.9?Update????????
???http://www.nihs.go.jp/dig/sireport/weekly6/09080502.pdf

Early Communication about an Ongoing Safety Review of Tiotropium (marketed as Spiriva HandiHaler)(FDA 2008.10.7)

???????????????????Vol.6?No.22?????????
??http://www.nihs.go.jp/dig/sireport/weekly6/22081030.pdf

???????????????????????????????????????????????????????????

???COPD Medicines: Risky or Safe??WebMD 2008.9.23?
??http://www.webmd.com/news/20080923/copd-medicines-risky-safe
????Leading COPD Drugs Tied to Stroke, Heart Attack
??????Healthday 2008.9.24)
??http://www.healthday.com/Article.asp?AID=619626

2010?1?15????????

Topに戻る  

コメント (2)

  1. FDA?2010?1?14?????????????????????????????????

    FDA Updates Earlier Guidance on Respiratory Treatment Spiriva HandiHaler
    Current data do not support increased risks for stroke, heart attack, or death
    (FDA 2010.1.14)
    http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm197649.htm

    Follow-Up to the October 2008 Updated Early Communication about an Ongoing Safety Review of Tiotropium (marketed as Spiriva HandiHaler) ?FDA 2010.1.14?

    投稿者 by ???????? — 2010年1月15日(金)17:13

  2. ????????

    ?????????????FDA??????????????1?15??
    ?http://intmed.exblog.jp/9667301/

    ??????????????11?19???????Pulmonary-Allergy Drugs Advisory Committee Meeting??????????????????

    November 19, 2009: Pulmonary-Allergy Drugs Advisory Committee Meeting Announcement
    ?FDA?
    ?http://www.fda.gov/AdvisoryCommittees/Calendar/ucm183398.htm

    ??????????

    投稿者 by ???????? — 2010年1月15日(金)21:50

現在、この記事へのコメントは頂いておりません。

Copyright(C) Ryomo Apotheker Network, All rights reserved, since 2004